Navigation Links
Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
Date:11/2/2009

e case of diabetic ulcers typically includes surgical debridement and off-loading. ExcellagenXL is expected to be indicated for use at two-week intervals (with weekly outer dressing changes) as an adjunct to surgical debridement, and supplied in a sterile single-use syringe along with a sterile flexible application needle to facilitate topical administration over the wound site. ExcellagenXL will be stored at standard refrigeration temperature (2 degrees C - 8 degrees C).

Cardium also announced plans to develop additional new product opportunities by incorporating other agents into Excellagen formulations, including antimicrobials, DNA and/or other biologics, which are designed to address particular wound healing and other tissue repair applications.

"We are pleased to announce plans to submit our FDA 510(k) premarket notification of our ExcellagenXL collagen-based topical gel. The 510(k) clearance process provides us with a potential near-term opportunity to introduce this product into the rapidly-growing market for advanced wound care. Applying our specialized formulation know-how and the unique properties of our collagen-based matrix technology, we also look forward to introducing additional Excellagen-based products in the near future," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 200
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cardium Completes $6.0 Million Registered Direct Offering
2. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
3. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
4. Cardium Regains Listing Compliance with NYSE Amex
5. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
6. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
7. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
8. Cardium Completes $3.5 Million Credit Facility
9. Cardium Announces Retirement of Director
10. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
11. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 ... has announced the addition of the ... 2018" report to their offering. ... Lack of data protection and old security ... codes have driven the growth of biometric ...
(Date:6/19/2013)... June 19, 2013   NineSigma , Inc., of ... year following its launch, NineSights.com is now ... point for the worldwide community of innovators. ... environmental sustainability experts, NineSights stands out for its large ... scientific and technical disciplines, all vetted by NineSigma. The ...
(Date:6/19/2013)... June 19, 2013 BioConvergence team ... speaking faculty at 2013’s BioLogistics Summit in San ... coordinated by Cold Chain IQ and IQPC, addressed ... “complexity” is, in part, attributed to current trends ... “Implicit within these trends is an increase in ...
(Date:6/19/2013)... 2013 Adding to their already extensive ... with Simport’s Dropette® and Heathrow Scientific disposable plastic ... doing basic biology, chemistry and any type of liquid ... over 35 years, Simport has been supplying the science ... like the Simport Dropette®. Simport’s Dropette® is a one-piece ...
Breaking Biology Technology:Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... VANCOUVER, April 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... global specialty pharmaceutical and,medical device company, today ... the U.S. Food and Drug Administration (FDA) ... Catheter (CVC) in,the United States., "The ...
... with Increased Investment in ... Research & Development, DEERFIELD, Ill., April 17 ... for,the first quarter of 2008, and raised its financial outlook for the ... million, a 6,percent increase compared to $403 million in the first quarter ...
... and more transparency in federal risk research investment, the ... rather than a foregone conclusion, says Dr. Andrew Maynard, ... Nanotechnologies (PEN). This sentiment was voiced today by Dr. ... Committees hearing on the National Nanotechnology Initiative Amendments Act ...
Cached Biology Technology:Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 2Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 3Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 4Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 5Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 2Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 3Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 4Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 5Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 6Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 7Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 8Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 9Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 10Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 11Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 12Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 13Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 14Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 15Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 16Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 17Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 18Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 19Limited transparency in federal nanotech research may hamper development 2
(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...
(Date:6/18/2013)... University, sophisticated computational models and advances in graphical ... interplay between genomic data, virus structure and the ... for replication. , "We hope that ... researchers alter virus assembly, leaving viruses unable to ... of the scientific paper describing the technique, published ...
(Date:6/18/2013)... National Institutes of Health has awarded $12.7 million ... selection of pharmaceutical industry compounds to explore new ... Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. The ... for Existing Molecules, is led by the National ... by the NIH Common Fund. , The process ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... experimental drug prevented and treated both type 2 diabetes ... unhealthy diets and were genetically predisposed to these common ... on June 6, 2007. The team was led by ... Genetics and Complex Diseases at the Harvard School of ...
... very cold case: the disappearance of the last woolly mammoths, ... according to a June 7th report published online in Current ... the bones, teeth, and tusks of the extinct mammoths revealed ... interglacial period. After the mammoths’ migration, the population apparently leveled ...
... University of Minnesota researchers report that umbilical cord ... outcomes than bone marrow transplants, according to an ... for International Blood and Marrow Transplant Research (CIBMTR), ... the first study that directly compares matched bone ...
Cached Biology News:In mice, drug protects against diabetes and atherosclerosis 2In mice, drug protects against diabetes and atherosclerosis 3In mice, drug protects against diabetes and atherosclerosis 4Ancient DNA traces the woolly mammoth's disappearance 2Research shows cord blood comparable to matched bone marrow 2Research shows cord blood comparable to matched bone marrow 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... Plus Microsphere/Microarray Stabilizer is an aqueous solution ... other non-toxic chemicals in a PBS buffer ... This product contains a combination of ... preservative. StabilCoat Plus Stabilizer provides optimum ...
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
... data acquisition, analysis and experiment control ... data with on-line and off-line analysis. ... built-in script language allowing the user ... exact requirements. Applications range from basic ...
Biology Products: